Utsunomiya Hiroki, Ito Kiyoshi, Suzuki Takashi, Kitamura Takako, Kaneko Chika, Nakata Taisuke, Niikura Hitoshi, Okamura Kunihiro, Yaegashi Nobuo, Sasano Hironobu
Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.
Clin Cancer Res. 2004 Sep 1;10(17):5850-6. doi: 10.1158/1078-0432.CCR-04-0040.
Intratumoral metabolism and synthesis of estrogens are considered to play important roles in the pathogenesis and/or development of human endometrial carcinoma. Steroid sulfatase hydrolyzes biologically inactive estrogen sulfates to active estrogens, whereas estrogen sulfotransferase sulfonates estrogens to estrogen sulfates. However, the status of steroid sulfatase and/or estrogen sulfotransferase in human endometrial carcinoma has not been examined.
We first examined the expression of steroid sulfatase and estrogen sulfotransferase in 6 normal endometrium and 76 endometrial carcinoma using immunohistochemistry to elucidate the possible involvement of steroid sulfatase and estrogen sulfotransferase. We then evaluated the enzymatic activity and the semiquantitative analysis of mRNA using reverse transcription-PCR in 21 endometrial carcinomas. We correlated these findings with various clinicopathological parameters including the expression of aromatase, 17beta-hydroxysteroid dehydrogenase type 1 and type 2.
Steroid sulfatase and estrogen sulfotransferase immunoreactivity was detected in 65 of 76 (86%) and 22 of 76 (29%) cases, respectively. Results of immunoreactivity for steroid sulfatase and estrogen sulfotransferase were significantly correlated with those of enzymatic activity and semiquantitative analysis of mRNA. No significant correlations were detected among the expression of the enzymes involved in intratumoral estrogen metabolism. There was a significant correlation between steroid sulfatase/estrogen sulfotransferase ratio and clinical outcomes of the patients. However, there were no significant differences between steroid sulfatase or estrogen sulfotransferase and estrogen receptor, progesterone receptor, Ki67, histologic grade, or clinical outcomes of the patients.
Results of our study demonstrated that increased steroid sulfatase and decreased estrogen sulfotransferase expression in human endometrial carcinomas may result in increased availability of biologically active estrogens and may be related to estrogen-dependent biological features of carcinoma.
肿瘤内雌激素的代谢和合成被认为在人类子宫内膜癌的发病机制和/或发展过程中发挥重要作用。类固醇硫酸酯酶将无生物活性的雌激素硫酸盐水解为活性雌激素,而雌激素磺基转移酶则将雌激素磺化为雌激素硫酸盐。然而,人类子宫内膜癌中类固醇硫酸酯酶和/或雌激素磺基转移酶的状态尚未得到研究。
我们首先使用免疫组织化学方法检测了6例正常子宫内膜和76例子宫内膜癌中类固醇硫酸酯酶和雌激素磺基转移酶的表达,以阐明类固醇硫酸酯酶和雌激素磺基转移酶可能的参与情况。然后,我们使用逆转录聚合酶链反应对21例子宫内膜癌进行了酶活性评估和mRNA的半定量分析。我们将这些结果与各种临床病理参数相关联,包括芳香化酶、17β-羟类固醇脱氢酶1型和2型的表达。
在76例病例中的65例(86%)和76例病例中的22例(29%)中分别检测到类固醇硫酸酯酶和雌激素磺基转移酶免疫反应性。类固醇硫酸酯酶和雌激素磺基转移酶免疫反应性结果与酶活性和mRNA半定量分析结果显著相关。肿瘤内雌激素代谢相关酶的表达之间未检测到显著相关性。类固醇硫酸酯酶/雌激素磺基转移酶比值与患者的临床结局之间存在显著相关性。然而,类固醇硫酸酯酶或雌激素磺基转移酶与雌激素受体、孕激素受体、Ki67、组织学分级或患者的临床结局之间没有显著差异。
我们的研究结果表明,人类子宫内膜癌中类固醇硫酸酯酶表达增加和雌激素磺基转移酶表达降低可能导致生物活性雌激素的可用性增加,并且可能与癌的雌激素依赖性生物学特征有关。